Last $34.81 USD
Change Today -0.20 / -0.57%
Volume 445.8K
ALR On Other Exchanges
Symbol
Exchange
New York
Berlin
As of 8:04 PM 08/20/14 All times are local (Market data is delayed by at least 15 minutes).

alere inc (ALR) Snapshot

Open
$35.00
Previous Close
$35.01
Day High
$35.21
Day Low
$34.50
52 Week High
07/2/14 - $40.80
52 Week Low
09/30/13 - $30.14
Market Cap
2.9B
Average Volume 10 Days
483.1K
EPS TTM
$-0.50
Shares Outstanding
83.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ALERE INC (ALR)

alere inc (ALR) Related Businessweek News

View More BusinessWeek News

alere inc (ALR) Details

Alere Inc. provides diagnostics and services for cardiology, infectious disease, toxicology, and diabetes in the United States and internationally. The company operates in three segments: Professional Diagnostics, Health Information Solutions, and Consumer Diagnostics. The Professional Diagnostics segment provides diagnostic test products and other in vitro diagnostic tests to medical professionals and laboratories for detection of diseases and conditions in the areas of cardiology, infectious diseases, toxicology, diabetes, oncology, and women’s health, as well as offers connected device technologies. The Health Information Solutions segment offers integrated programs and services focused on wellness, disease and condition management, productivity enhancement, and informatics. This segment’s health improvement programs comprise patient self-testing, condition and case management, women’s and children’s health, and health and wellness programs. The Consumer Diagnostics segment provides products for over-the-counter pregnancy and fertility/ovulation test markets; and over-the-counter drug tests for at-home testing and cholesterol monitoring under the First Check brand name, as well as vaginal gel for the treatment of bacterial vaginosis. Alere Inc. markets its professional diagnostic products to hospitals, reference laboratories, physician offices, and other point-of-care settings through its sales force and distribution networks; health information solutions primarily to commercial and governmental health plans, self-insured employers, government and governmental programs, pharmaceutical companies, and physicians through sales force and channel partners; and consumer drug testing products through retail drug stores, drug wholesalers, groceries, and mass merchandisers. The company was formerly known as Inverness Medical Innovations, Inc. and changed its name to Alere Inc. in July 2010. Alere Inc. was founded in 2001 and is headquartered in Waltham, Massachusetts.

17,600 Employees
Last Reported Date: 03/3/14
Founded in 2001

alere inc (ALR) Top Compensated Officers

Interim Chief Executive Officer, Interim Pres...
Total Annual Compensation: $1.1M
Chief Financial Officer, Vice President and T...
Total Annual Compensation: $408.8K
Compensation as of Fiscal Year 2013.

alere inc (ALR) Key Developments

Alere To Divest Assets

Alere Inc. (NYSE:ALR) is looking to sell several parts of its business. Alere Inc. announced plans to make budget cuts in and look into the possible sale of several parts of its business while it focuses on its core diagnostics products. Namal Nawana, Interim Chief Executive Officer and President of Alere Inc. mentioned oncology, women's health, veterinary products and "certain speculative R&D projects" as potential areas to cut, but the overwhelming focus of a possible sale would come in what the company calls Connected Health.

Alere Inc. Announces Consolidated Financial Results for the Second Quarter and Six Months Ended June 30, 2014

Alere Inc. announced consolidated financial results for the second quarter and six months ended June 30, 2014. Net revenue of $737.9 million for the second quarter of 2014, compared to $764.0 million for the second quarter of 2013. Non-GAAP adjusted net revenue was $738.3 million for the second quarter of 2014, compared to $764.6 million for the second quarter of 2013. Net loss of $55.0 million attributable to common stockholders and respective net loss per diluted common share of $0.67 for the second quarter of 2014, compared to net loss of $65.9 million attributable to common stockholders and respective net loss per diluted common share of $0.81 for the second quarter of 2013. Non-GAAP adjusted net income per diluted common share of $0.42 for the second quarter of 2014, compared to non-GAAP adjusted net income per diluted common share of $0.64 for the second quarter of 2013. Free cash flow for the second quarter of 2014 was a negative $7.6 million, reflecting cash flow from operations of $19.3 million, offset by capital expenditures of $26.9 million. Cash flow from operations during the quarter was adversely impacted by the payment of $9.1 million of severance charges associated with a workforce reduction, $6.2 million of payments associated with costs incurred related to planned dispositions and $16.7 million of contingent purchase price payments in excess of acquisition date accruals. Additionally, cash flow from operations for the second quarter reflects the payment of $49.6 million of semiannual interest payments on Senior and Senior Subordinated Notes. Non-GAAP EBITDA for the second quarter of 2014 was $110.2 million, which reflects adjustments to add back non-interest related restructuring charges of $15.8 million, $0.1 million of acquisition-related costs and $11.6 million of costs associated with potential business dispositions. Non-GAAP EBITDA for the second quarter of 2013 was $166.6 million, which reflects adjustments to add back non-interest related restructuring charges of $8.0 million and $0.4 million of acquisition-related costs. Net debt was $3.38 billion as of June 30, 2014, compared to net debt of $3.56 billion as of June 30, 2013. Operating loss was $8,759,000, compared to operating income of $44,404,000 for the last year. Loss before provision for income taxes was $58,291,000, compared to $46,986,000 for the last year. Non-GAAP adjusted operating income was $102,318,000, compared to $143,850,000 for the last year. Net revenue was $1,454,565,000, compared to $1,503,234,000 for the last year. Operating income was $17,181,000, compared to $74,893,000 for the last year. Loss before benefit for income taxes was $79,673,000, compared to $74,366,000 for the last year. Net loss attributable to the company and subsidiaries was $55,876,000 or $0.81 per basic and diluted share, compared to $48,119,000 or $0.72 per basic and diluted share for the last year. Non-GAAP adjusted operating income was $216,322,000, compared to $271,929,000 for the last year. Non-GAAP adjusted net income available to common stockholders was $82,948,000 or $0.97 per basic and diluted share, compared to $98,593,000 or $1.16 per basic and diluted share for the last year. Non-GAAP adjusted net revenue was $1,455,357,000, compared to $1,504,469,000 for the last year. Cash flow from operating activities was $125,167,000. Capital expenditure was $54,430,000. Free cash flow was $70,737,000.

Alere Inc. to Report Q2, 2014 Results on Aug 04, 2014

Alere Inc. announced that they will report Q2, 2014 results at 9:00 AM, Eastern Standard Time on Aug 04, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALR:US $34.81 USD -0.20

ALR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bio-Rad Laboratories Inc $120.00 USD -0.79
BioMerieux €78.00 EUR +0.57
Hill-Rom Holdings Inc $43.30 USD +0.04
Steelcase Inc $15.83 USD -0.16
STERIS Corp $55.00 USD -0.01
View Industry Companies
 

Industry Analysis

ALR

Industry Average

Valuation ALR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.0x
Price/Book 2.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALERE INC, please visit www.alere.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.